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osting by EAbstract Jaccoud’s arthropathy (JA) is a chronic, deforming, non-erosive arthropathy occurring
in a subset of patients with systemic lupus erythematosus (SLE). In this research we aimed to eval-
uate clinical and immunological features in patients with SLE complicated by JA. Eighty seven con-
secutive SLE patients with a history of arthritis were included in the present study. These patients
were subdivided according to ‘‘Jaccoud’s arthropathy index’’ as follows: non-deforming arthropa-
thy, mild deforming and deﬁnite Jaccoud. Demographic data, disease activity and disability were
recorded. Rheumatoid factor (RF), anti-cardiolipin antibodies (ACL), antiSSA/Ro, and anti
SSB/La antibodies, were assessed in all patients. We found clinical deforming arthropathy in 12
patients, among whom seven had deﬁnite JA. Both the mean duration of the disease and of arthritis
were longer in the JA group compared to the non-deforming arthropathy group. JA patients
presented a trend toward a lower quality of life. The prevalence of Sicca syndrome (SS) and
antiphospholipid syndrome were signiﬁcantly higher in the JA group than in the patients with
non-deforming arthropathy (p= 0.011 and 0.012, respectively). ACL and RF were more frequent476767; fax: +20 2 37228788.
com (I.H. Bassyouni).
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328 I.H. Bassyouni et al.among patients with JA (p= 0.013 and 0.036; respectively). These data suggest that JA is not rare
and represents a subset of SLE with speciﬁc clinical and serological features. Future studies are
needed to reveal the pathogenesis, the genetic association, the prevention, the stabilization and
the appropriate cure for these patients.
ª 2011 Cairo University. Production and hosting by Elsevier B.V. All rights reserved.Introduction
Joint involvement in systemic lupus erythematosus (SLE) is
one of the earliest and most common manifestations of this
multi-systemic disease [1]. Lupus arthropathy is usually tran-
sient, migratory, non-erosive and reversible [2]. Occasionally,
it may take a more chronic course, leading to non-erosive joint
deformities, although erosive features indistinguishable from
rheumatoid arthritis occur rarely [3].
Non-erosive arthropathy with marked articular dislocation
or subluxation has been ﬁrst described by Jaccoud in patients
with rheumatic fever. Later investigators have reported com-
plications of Jaccoud’s arthropathy (JA) in other rheumatic
diseases such as SLE [1–3]. JA has not been adequately evalu-
ated because it is more easily manageable compared to life-
threatening involvements such as renal disorders [1].
Given the wide variety of clinical features associated with
SLE, there have been many attempts to identify subsets of pa-
tients for whom a given antibody speciﬁcity can be identiﬁed
with JA. Several associations, such as the presence of antibod-
ies against U1 RNP, RA 33, SS-A/Ro and SS-B/La, anti car-
diolipin (aCL), lupus anticoagulants (LAC), and anti-mutated
citrullinated vimentin, have been reported previously [1,4,5].
To our knowledge, no previous studies had dealt with the
description of JA and its relation to clinical and immunologi-
cal proﬁles among Egyptian SLE patients with arthritis. In
that ﬁeld, well-designed replication studies in populations with
different ethnic backgrounds are necessary.
In this research, we aimed to evaluate clinical and immuno-
logical features in patients with SLE complicated by JA.
Patients and methods
A group of 87 consecutive patients affected by SLE with a doc-
umented history of arthritis were prospectively assessed. They
all attended the Department of Rheumatology and Rehabilita-
tion Kasr El-Eini Hospital, Cairo University, and fulﬁlled the
American College of Rheumatology (ACR) criteria for the
diagnosis of SLE [6]. There were 83 women and four men with
a mean age of 25.07 ± 6.77 years (14–47 years); the mean
duration of SLE was 7.20 ± 4.06 years (5–17 years). Disease
activity was assessed for all the patients using the SLE disease
activity index (SLEDAI) [7]. The deﬁnition of JA had been
based on clinical criteria (reversible articular deformities) to-
gether with the absence of bone erosions on radiographs.
These patients were clinically evaluated, underwent a detailed
physical examination and had their medical records revised.
Articular evaluation
Physical examination included a detailed standardized exami-
nation of the hands and feet. The following items were evalu-
ated in each case: signs of arthritis of wrists and small joints ofthe hand, ulnar deviation of ﬁngers, MCP subluxation, swan
neck deformities of the ﬁngers, Z deformity of the thumb, bou-
tonnie`re deformities and deformities of the feet. Previous his-
tory with special attention to the presenting manifestation of
SLE, cumulative ACR criteria, and time between arthritis
and the development of deformity, were obtained from medi-
cal records. Deforming arthropathy was considered positive
if there is deviation from any of the metacarpus ﬁnger axes (as-
sessed with an angle goniometer) [8]. Those patients were then
assessed for the presence of deﬁnite Jaccoud’s arthropathy,
using a JA index [9], which is dependent upon the different
clinical symptoms and the severity of the deformities (details
in Table 2). Patients who had scores exceeding ﬁve points were
considered to have JA. The remaining patients were classiﬁed
as having mild deforming arthropathy. Assessment of disabil-
ity was done using the Health Assessment Questionnaire
Disability Index (HAQ-DI) [10]. All the patients had recent
X-ray ﬁlm of the hands (postero-anterior view).
Organ system assessment
Clinical features were deﬁned according to the ACR 1982 re-
vised classiﬁcation criteria for SLE [6]. Neuropsychiatric mani-
festations were deﬁned according to theACRnomenclature and
case deﬁnitions for neuropsychiatric lupus [11]. Renal involve-
ment was deﬁned as glomerulonephritis on biopsy or with dia-
stolic blood pressure >90 mm Hg, edema requiring diuretic
therapy, proteinuria >0.5 g/24 h, abnormal urinary sediment
manifested by RBC and leukocytes, creatinine clearance
<60 ml/min or raised serum creatinine level >124 umol/l. Re-
nal biopsy was available for 22 patients and evaluated according
to the World Health Organization (WHO) classiﬁcation of his-
tological types of lupus nephritis [12]. Antiphospholipid syn-
drome was considered to be present if at least one of deep
venous thrombosis (DVT), arterial thrombosis conﬁrmed by
Doppler imaging, or pregnancy morbidity was present, in addi-
tion to thepresence ofLACand/or aCL [13].Other organ system
affections were deﬁned as previously described [14].
Laboratory and immunological investigations
Routine laboratory examinations were collected from the pa-
tients’ records. Detection of IgM rheumatoid factor (RF)
was done by latex agglutination (Rose-Waaler test), antinu-
clear antibody (ANA) by indirect immunoﬂuorescence on
Hep-2 cells, and anti double stranded DNA (anti-dsDNA)
antibody using a modiﬁed Farr assay. Anti-Ro/SSA and
anti-La/SSB were searched by immunodiffusion (Immuno-
Concepts, Sacramento, CA, USA). Anti-cardiolipin antibodies
(aCL) were detected by ELISA using commercial kit (Immu-
noConcepts, Sacramento, CA, USA). Lupus anticoagulants
(LAC) were assessed by the dilute Russell’s viper venom time
and conﬁrmatory tests [15].
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tee and informed consent was obtained from all the patients.
Statistical analysis
The statistical package for social sciences (SPSS) version 10
(LEAD Technology Inc., Charlotte, NC, USA) was used to
analyze the data. Data were statistically described in terms
of range, mean ± standard deviation (±SD), frequencies
(number of cases) and relative frequencies (percentages) when
appropriate. Statistical analysis was performed using the chi
square method with Yates’ correction, Fisher’s exact test.
The Student t-test was used to compare the differences of the
mean of two groups in ordinal variables. A difference was con-
sidered to be statistically signiﬁcant when the probability (p)
value was <0.05.
Results
We identiﬁed 12 patients with clinical deforming arthropathy
of the hands. Among them, seven patients had a JA index
greater than ﬁve points (>5) and were considered to have def-
inite JA.
The mean age of JA patients was insigniﬁcantly different
compared to patients with mild deformity and those with
non-deforming arthropathy. Both the disease duration and
the duration of arthritis were longer in JA patients than in
those with non-deforming arthropathy (p= 0.000 and 0.04,
respectively).
Lupus activity using a SLEDAI score was comparable be-
tween the three groups. The mean score of the disability was
higher in the JA group compared to the other groups; how-
ever, differences were not signiﬁcant (p> 0.05). Demographic
data, activity and disability of the three types of arthritis are
presented in Table 1.
Arthritis was presented as the initial disease manifestation
in six out of seven JA patients. Their early symptoms consisted
of morning stiffness and/or minimal to mild arthralgias and
the duration from the initial joint symptoms to the typical
deformity was 12.5 ± 5.3 years.
The JA index and articular indices of the two types of
deforming arthropathy are presented in Table 2. Foot involve-
ment was observed in three patients of the JA group, two had
hullux valgus and one had metatarsophalangeal joint sublax-
ation. Laxity of ligaments, other than those of hands and feet,
were not observed in any other joints of the body.
The radiological ﬁndings of the wrists in the JA group in-
cluded joint space narrowing in one patient, cystic changesTable 1 Demographic data, activity and disability of the three type
Patient characteristic Mild deforming (n= 5)
Age (years) 25.0 ± 4.52
Disease duration (years) 6.20 ± 2.40
Arthritis duration 5.97 ± 3.61
SLEDAI 12.80 ± 8.50
HAQ-DI 1.2 ± 0.7
Data are mean ± SD.
SLEDAI = systemic lupus erythematosis disease activity index, HAQ-D
a Signiﬁcant compared to mild deforming group.
b Signiﬁcant compared to non-deforming group.in two patients, bone irregularity in two patients, and ulnar
laxation in one patient. Bone irregularities, cystic changes,
and MCP hooks, were found in the ﬁngers of three
patients.
In order to evaluate whether JA patients constitute, apart
from the presence of deformities, a distinct subgroup within
the range of SLE, we compared the clinical characteristics
and serological ﬁndings of seven patients with deﬁnite JA
and with those of the group of our SLE population with
non-deforming arthropathy (Table 3). Renal affection was
present in 52/87 patients of our patient cohort; none of our pa-
tients suffered from chronic renal failure. Renal affection was
less frequent among the JA group than the non-deforming
group; however, the difference was insigniﬁcant (p= 0.08).
The prevalence of Sicca syndrome (SS) and antiphospholipid
syndrome were signiﬁcantly higher in the JA group compared
with the patients with non-deforming arthropathy (p= .0.011
and 0.012, respectively). ACL and IgM RF were more frequent
among patients with JA (p= 0.013 and 0.036; respectively).
No signiﬁcant differences were found with respect to other
clinical and serological characteristics between the two groups.
The group with mild deforming arthropathy did not differ sta-
tistically in any aspect (from the SLE patients without deform-
ing arthropathy (data not shown).Discussion
Joint involvement occurs in the majority of patients with SLE
and is one of the initial manifestations, ranging from minor
arthralgia to severe deforming arthritis, or so-called JA [1].
JA of the hands was identiﬁed in seven (8%) of our series of lu-
pus patients with arthritis. JA is noteworthy to be recognized
since it is difﬁcult to manage and may trouble patients’ quality
of life [16]. The estimated prevalence of JA in the published lit-
erature ranged from 3% to 10% according to the population
studied and their criteria of patient selection [5,9,16,17]. JA
was ﬁrst described in 1867 in patients with rheumatic fever
[18]; later it was observed in patients with SLE [5,9,16,17], in
other connective tissue diseases [19–21], and in other different
clinical conditions [22–24]. Regardless of the associated disease
condition, the etiopathogenesis of JA is still unknown. In the
present series of SLE patients, it was observed that the group
with JA had a signiﬁcantly longer duration both of the disease
and of arthritis compared to the non-deforming group. Spronk
et al. have observed that high disease activity for prolonged
periods of time may lead to the development of hand deformi-
ties [9]. Furthermore, previous studies have conﬁrmed that typ-
ical JA appears to be a late manifestation of longstandings of arthropathy.
Jaccoud’s (n= 7) Non-deforming (n= 75)
27.57 ± 7.76 25.12 ± 6.91
13.28 ± 2.65a,b 6.65 ± 3.68
9.62 ± 4.97b 5.61 ± 4.93
13.57 ± 9.08 17.45 ± 8.36
1.5 ± 1.2 0.9 ± 0.9
I = Health Assessment Questionnaire Disability Index.
Table 2 Jaccoud arthropathy index of the hand of two types of deforming arthropathy.
Jaccoud arthropathy index Mild deforming patients
no (n= 5)
Jaccoud’s patients no
(n= 7)
Swan neck deformity 1–4 ﬁngers (2 points) 1/5 3/7
5–8 ﬁngers (3 points) 0/5 3/7
Ulnar deviation 1–4 ﬁngers (2 points) 2/5 4/7
5–8 ﬁngers (3 points) 0/5 2/7
Boutonnie`re deformity 1–4 ﬁngers (2 points) 1/5 3/7
5–8 ﬁngers (3 points) 1/5 1/7
Limited MCP extension 1–4 ﬁngers (2 points) 2/5 2/7
5–8 ﬁngers (3 points) 0 2/7
Z deformity One thumb (1 point) 1/5 1/7
Both thumbs (2 points) 1/5 1/7
MCP=metacarpophalangeal joints.
Table 3 Clinical and immunological characteristics of the
three groups of patients with lupus arthropathy.
Mild-deforming
(n= 5)
Jaccoud
(n= 7)
Non-deforming
(n= 75)
ACR criteria of SLE
Malar rash 2 (40) 4 (57.1) 45 (60)
Discoid rash 1 (20) 0 8 (10.6)
Photosensitivity 2 (40) 4 (57.1) 47 (62.6)
Oral Ulcers 2 (40) 2 (28) 27 (36)
Arthritis 5 (100) 7 (100) 75 (100)
Serositis 2 (40) 5 (71.4) 51 (68)
Renal disorders 2 (40) 2 (28) 48 (64)
Neuropsychiatric 1 (20) 1 (14.2) 13 (17.3)
Haematological disease 1 (20) 3 (42.8) 16 (21.3)
Anti-nuclear ab 5 (100) 7 (100) 75 (100)
Anti-dsDNA 2 (40) 3 (42.8) 51 (68)
Other clinical manifestations
Anti-phospholipid
syndrome
1 (20) 4 (57.1)* 9 (12)
Sicca syndrome 1 (20) 3 (42.8)* 4 (5)
Cardiopulmonary 1 (20) 2 (28) 26 (34.6)
Cutaneous vasculitis 1 (20) 3 (42.8) 14 (18.6)
Other serological ﬁndings
RF (IgM) 1 (20) 3 (42.8)* 7 (9)
aCL (IgG and/or M) 1 (20) 5 (71.4)* 17 (22.6)
LAC 1 (20) 3 (42.8) 9 (12)
Anti-Ro/anti-La 1 (20) 3 (42.8) 13 (17.3)
Data are number of patients (%); anti-dsDNA, anti-double stran-
ded DNA; RF, rheumatoid factor; aCL, anticardiolipin; LAC,
lupus anticoagulant.
* Signiﬁcantly different compared to the non-deforming group.
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occurring over a long duration together with persistent teno-
synovitis, might cause capsule retraction and ligamentous lax-
ity leading to muscle imbalance, with subsequent
development of JA [1,25]. Based on histological ﬁndings,
microvascular changes and mild but typical ﬁbrous synovitis
with little or no round cell inﬁltration have been found in JA,
which have been mainly located in the articular capsule and
tendons, leading to later ﬁbrosis and deformity [17]. These ﬁnd-
ings have been conﬁrmed by ultrasonographic and magneticresonance imaging (MRI) of the hands in JA where capsular
swelling, and edematous and proliferative tenosynovitis were
the most prominent ﬁndings [26,27]. Recently, Sa´ Ribeiro
et al. have performed a detailed MRI analysis of the hands of
20 patients with JA secondary to SLE. They found some degree
of synovitis, bone cysts, subchondral bone edema, and tiny
areas of erosion, which were not detected on conventional
radiographs of the hands [28].
Previous published studies have shown conﬂicting results
with respect to the association of JA with auto antibodies in
lupus patients. Rheumatoid factor and ACL were found asso-
ciated with JA in our patient cohort. A possible role for RF
has been suggested in the pathogenesis of JA by participating
in the formation of immune complexes and, as such, acting as
a local inducer of an inﬂammatory reaction [1]. Numerous
authors have observed that the patients with JA frequently dis-
play elevated C-reactive protein [9], RF [1], anti-cardiolipins
[1,17,29], anti-SSA/Ro and anti-SSB/La antibodies [8,30]. An-
other study has demonstrated an association between JA in the
patients with SLE and anti-thyroglobulin antibodies [31]. A re-
cent study conducted in Brazil comparing the frequency of var-
ious autoantibodies such as anti-dsDNA, anti-SSA/Ro, anti-
SSB/La, anti-cyclic citrullinated peptides and anti-mutated cit-
rullinated vimentin in SLE patients, with or without JA, found
no statistically signiﬁcant differences between the groups ex-
cept for anti-dsDNA and anti-mutated citrullinated vimentin
antibodies [5]. The variable results presented in the literature
might be related to ethnical or methodological differences.
Whether these antibodies have an etiopathogenic role in JA
is still entirely unknown.
We described an association of anti-phospholipid syndrome
and JA. Van Vugt et al. [17] have previously described such an
association and have suggested that small vessel vasculopathy
may play a part in the genesis of the periarticular ﬁbrosis. A
growing body of evidence for this hypothesis can be found in
‘‘ﬁbrin like material obliterating small vessel lumens’’
described in synovial biopsy specimens [32]. Bywaters [18]
has already reported a correlation with mitral stenosis and
Libman-Sacks endocarditis; both are known to be associated
with antiphospholipid syndrome. One recent study has demon-
strated an association between the presence of valvular heart
disease and JA in the patients with SLE [33].
The high prevalence of SS in our patients with JA was con-
sistent with previous observations [4,8,34]. Villiaumey et al.
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eases and raised the possibility that lacrimal and salivary gland
involvement in SS can reﬂect a systemic disorder, including
synovial inﬂammation, which may lead to a capsulo-ligamen-
tous dislocation or JA.
The association between lupus nephritis and JA is, how-
ever, unclear: Van Vugt et al. have found renal affection to
be signiﬁcantly less in their JA group with SLE than the
non-deforming group [17]. On the other hand, Zeier has de-
scribed a case with glomerulonephritis and JA and coined
the term Jaccoud’s nephropathy [36]. A close association has
been described between the presence of chronic renal failure
complicated by secondary hyperparathyroidism in SLE pa-
tients, and responsibility for tendinous elongation and/or Jac-
coud’s syndrome [37]. The rarity of renal involvement and
chronic renal failure in our JA patients might be related to
the elevated RF, which has been considered as a protecting
factor against renal affection [29].
Conclusion
To sum up, in our patients with lupus arthropathy JA is not
rare and seems to be more frequent among patients with long
disease duration. JA patients presented a trend toward a lower
quality of life (using HAQ-DI) compared with the patients
with SLE without deforming arthropathy. JA is notable for
positive association with IgM RF, SS, anti-phospholipid syn-
drome, with unique radiological features, and foot involve-
ment. On the other hand, those with a ‘‘mild deforming
arthropathy’’ do not seem to differ in any respect from SLE
patients without deforming arthropathy. Future multicentre
studies, on a larger cohort, are needed to reveal the pathogen-
esis, the genetic association, the prevention, the stabilization
and the appropriate cure for these patients.
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